Extranodal nasal NK/T cell lymphoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:86879C86.0
Who is this for?
Show terms as
24Active trials58Specialists8Treatment centers1Financial resources

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Angiocentric T-cell lymphomaLethal midline granulomaNK/T-cell lymphomaNKTCLNasal T/natural killer-cell lymphoma
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jun 2026Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals — PHASE3

TrialNOT YET RECRUITING
Apr 2026Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE1

TrialRECRUITING
Mar 2026Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

Rong Tao — PHASE1, PHASE2

TrialNOT YET RECRUITING
Mar 2026PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Ruijin Hospital — PHASE2

TrialRECRUITING
Feb 2026Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

M.D. Anderson Cancer Center — PHASE1

TrialRECRUITING
Feb 2026A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Electra Therapeutics Inc. — PHASE1

TrialRECRUITING
Feb 2026Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL

Sun Yat-sen University

TrialNOT YET RECRUITING
Feb 2026Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

LIANG WANG — PHASE2

TrialNOT YET RECRUITING
Jan 2026Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

WEI XU — PHASE2

TrialNOT YET RECRUITING
Jan 2026EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Sun Yat-sen University — PHASE1, PHASE2

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Extranodal nasal NK/T cell lymphoma.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →
Phase 31 trial
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
Phase 3
Actively Recruiting
· Sites: Guangzhou, Guangdong · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 212 trials
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Phase 2
Active
PI: Alison Moskowitz, MD (Memorial Sloan Kettering Cancer Center) · Sites: Stanford, California; Basking Ridge, New Jersey +8 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
Phase 2
Actively Recruiting
· Sites: Shanghai · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
Phase 2
Actively Recruiting
· Sites: Beijing; Beijing +1 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase 2
Actively Recruiting
PI: Alison Moskowitz, MD (Memorial Sloan Kettering Cancer Center) · Sites: Miami, Florida; Chicago, Illinois +8 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Phase 2
Active
PI: Won Seog Kim (Samsung Medical Center, Republic of Korea) · Sites: Gwangju; Seoul +3 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
Phase 2
Active
· Sites: Guangzhou, Guangdong · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
Phase 2
Actively Recruiting
· Sites: Beijing, Beijing Municipality · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Phase 2
Actively Recruiting
PI: Yu Zhao, Graduate (Chief) · Sites: Beijing, Haidian · Age: 14–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
Phase 2
Actively Recruiting
· Sites: Seoul · Age: 19–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
Phase 2
Actively Recruiting
PI: Rong Tao, MD (Fudan Cancer Hospital) · Sites: Fuzhou, Fujian; Nantong, Jiangsu +4 more · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Phase 2
Actively Recruiting
· Sites: Busan; Daegu · Age: 19–65 yrs
View on ClinicalTrials.gov ↗I'm interested →
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
Phase 2
Actively Recruiting
PI: Stefano Luminari, MD (Ematologia, AUSL IRCCS Reggio Emilia) · Sites: Guangzhou; Shanghai · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 11 trial
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
Phase 1
Active
PI: Wen-Son Hsieh (Johns Hopkins Singapore) · Sites: Baltimore, Maryland; Shatin +3 more · Age: 21–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other2 trials
Circulating Tumor DNA in Peripheral T-cell Lymphomas
Actively Recruiting
PI: Francesco A d'Amore, MD, DMSc (Aarhus University Hospital and Aarhus University) · Sites: Aarhus, Central Jutland · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
Enrolling by Invitation
· Sites: Shanghai, China · Age: 18–70 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 58View all specialists →
ZP
ZHAO WEILI, PhD,MD
Specialist
PI on 1 active trial
YM
Ye Guo, MD
AUSTIN, TX
Specialist
PI on 9 active trials
JV
Julie M Vose
MANCHESTER, NH
Specialist
PI on 2 active trials
AM
Alison Moskowitz, MD
FAIRFIELD, CT
Specialist
PI on 6 active trials1 Extranodal nasal NK/T cell lymphoma publication
HM
Helen E Heslop, MD
HOUSTON, TX
Specialist
PI on 6 active trials
LM
Liang Wang, M.D.
Specialist
PI on 4 active trials
PM
Paolo Caimi, MD
CLEVELAND, OH
Specialist
PI on 5 active trials
RN
Ryotaro Nakamura
Duarte, California
Specialist

Rare Disease Specialist

PI on 6 active trials
CD
Colleen Delaney
OLD GREENWICH, CT
Specialist
PI on 3 active trials
YG
Yu Zhao, Graduate
Specialist
PI on 1 active trial
SG
Sai Huang, Graduate
Specialist
PI on 1 active trial
JM
Jonathan Moreira, MD
CHICAGO, IL
Specialist
PI on 2 active trials
TM
Thomas E. Witzig, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
NR
Nancy Wells, DNSc, RN
Specialist
PI on 2 active trials
WP
Won Seog Kim, MD, PhD
Specialist
PI on 6 active trials
YO
Yasuhiro Oki
HOUSTON, TX
Specialist
PI on 1 active trial
HL
Hongtao Liu
MADISON, WI
Specialist
PI on 4 active trials
JG
John Gerecitano
NEW YORK, NY
Specialist
PI on 1 active trial
KM
Kevin C Conlon, M.D.
IRVINE, CA
Specialist
PI on 8 active trials
PP
Pierluigi Porcu
PHILADELPHIA, PA
Specialist
PI on 2 active trials
IM
Issa F. Khouri, MD
SOUTH SAN FRANCISCO, CA
Specialist
PI on 4 active trials
BM
Brian Hill, MD
Specialist
PI on 1 active trial
PL
Patricia LoRusso
LANCASTER, NY
Specialist
PI on 4 active trials
SK
Shaji Kumar
Anchorage, Alaska
Specialist

Rare Disease Specialist

PI on 7 active trials
LB
Lihua Budde
DUARTE, CA
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

Folotyn

Acrotech Biopharma LLC

Folotyn Patient Support (Acrotech Patient Support)

Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Extranodal nasal NK/T cell lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Extranodal nasal NK/T cell lymphomaForum →

No community posts yet. Be the first to share your experience with Extranodal nasal NK/T cell lymphoma.

Start the conversation →

Latest news about Extranodal nasal NK/T cell lymphoma

Disease timeline:

New recruiting trial: Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: A Global Study of the PETAL Consortium

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

New recruiting trial: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

A new clinical trial is recruiting patients for Extranodal nasal NK/T cell lymphoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Extranodal nasal NK/T cell lymphoma

Are there clinical trials for Extranodal nasal NK/T cell lymphoma?

Yes — 20 recruiting clinical trials are currently listed for Extranodal nasal NK/T cell lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Extranodal nasal NK/T cell lymphoma?

25 specialists and care centers treating Extranodal nasal NK/T cell lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Extranodal nasal NK/T cell lymphoma?

1 patient support program are currently tracked on UniteRare for Extranodal nasal NK/T cell lymphoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.